T cell-mediated immunotherapy of metastases: state of the art in 2005.
Advances in cellular and molecular immunology have led to the development of strategies for effective augmentation of antitumour immune responses in cancer patients. This review focuses on the manipulation of T cell immunity either by active specific immunotherapy (ASI) using tumour vaccines, or by adoptive immunotherapy (ADI) with immune T cells. Such therapies offer exquisite specificity of tumour recognition based on the ability of the T cell to distinguish single amino acid differences in any protein from any compartment of the tumour cell. Examples are presented of clinical survival benefits for cancer patients by postoperative ASI with a modified autologous tumour vaccine of high quality. Furthermore, clinical studies employing ADI with T cells activated and expanded ex vivo have demonstrated 'proof of principle' that tumour-specific T cells are capable of mediating anticancer activity in vivo, as measured by regression of metastatic tumours. Translation of these findings into a standardised immunotherapy is, however, not easy and will require coordination and cooperation among academic, private and federal sectors.
Schirrmacher
Volker
V
German Cancer Research Center, Division of Cellular Immunology, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany. v.schirrmacher@dkfz-heidelberg.de
D000951:Antigens, Neoplasm / Q000276:immunology / Q000502:physiology; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D008967:Molecular Biology / Q000639:trends*; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology / Q000502:physiology; D014765:Viral Vaccines / Q000276:immunology / Q000627:therapeutic use
D000951:Antigens, Neoplasm; D014765:Viral Vaccines